Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor
Sign Up to like & getrecommendations! Published in 2020 at "ACS Medicinal Chemistry Letters"
DOI: 10.1021/acsmedchemlett.9b00568
Abstract: Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-XL inhibitor that selectively and potently induces apoptosis in BCL-XL-dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-XL inhibitor A-1155463… read more here.
Keywords: bcl inhibitor; discovery 1331852; 1331852 first; bcl ... See more keywords